Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
| Main Authors: | , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
BMJ Publishing Group
2019
|